长春瑞滨联合卡培他滨治疗晚期乳腺癌疗效观察

目的：观察长春瑞滨联合卡培他滨治疗晚期乳腺癌患者的疗效和不良反应。方法：长春瑞滨25mg/m2，第1、第8天静滴；卡培他滨2.0g/（m2·d），第1～第14天早晚各1次，餐后30min口服。21d为1个周期，最多接受8个周期化疗或至疾病进展。结果：46例患者共完成225个化疗周期，中位化疗5个周期。其中完全缓解（CR）2例，部分缓解（PR）17例，稳定（SD）17例，进展（PD）10例。总有效率（CR＋PR）为41.3%，疾病控制率（DCR）为78.3%，中位无进展生存期（TTP）为8.3个月，1、3年生存率分别为70.6%、27.6%。不良反应主要为血液学毒性、手足综合征及静脉炎，未发生治疗相关性死亡。结论：长春瑞滨联合卡培他滨方案是治疗晚期乳腺癌的有效方案，不良反应可以耐受。

Effect of vinorelbine combined with xeloda on treating the patients with advanced breast cancer

Objective： To explore the clinical efifcacy and tolerability of vinorelbine with xeloda for pa-tients with advanced breast cancer.Methods： Forty-six patients with advanced breast cancer were enrolled in the study. All patients were given 25 mg/m2 of vinorelbine on days 1 and 8, combined with 2.0 g/m2 of xeloda daily from day 1 to 14. The combined chemotherapy was repeated every 21 days as one cycle. Patients received a maximum chemotherapy of 8 cycles or until disease progression.Results： All the 46 patients completed 225 che-motherapy cycles with a 5-cycle median. Adverse events and clinical efifcacy were evaluated on all 46 patients. Complete remission （CR） in 2 patients, partial remission （PR） in 17 patients, stable disease （SD） in 17 patients, and progression of disease （PD） in 10 patients. The overall response rate （CR＋PR） was 41.3%, and the disease control rates （DCR） was 78.3%. The median time to progression （TTP） was 8.3 months, 1 year and three-year survival rates were 70.6% and 27.6%.The most commonly observed adverse events were hematologic toxicity＆amp;nbsp;and hand-foot syndrome and angeitis. No mortality occurred during the treatment.Conclusion： Vinorelbine com-bined with xeloda is an effective and safe chemotherapeutic regimen for advanced breast cancer, and the adverse reactions are well tolerated.